Drug-Coated vs Uncoated Percutaneous Transluminal Angioplasty in Infrapopliteal Arteries: Six-Month Results of the Lutonix BTK Trial
- 1 August 2019
- journal article
- research article
- Vol. 31 (8), 205-+
Abstract
Objectives. We hypothesized that a drug-coated balloon (DCB) could improve treatment efficacy while maintaining safety when compared with percutaneous transluminal angioplasty (PTA) for the treatment of atherosclerotic infrapopliteal arterial lesions. Methods. A total of 442 patients with angiographically significant lesions were randomized (2:1) to DCB or PTA. The primary safety and efficacy endpoints were freedom from major adverse limb events and perioperative death (MALE-POD) at 30 days, and freedom from vessel occlusion, clinically driven target-lesion revascularization (CD-TLR), and above-ankle amputation measured at 6 months. Success was achieved if safety between groups was non-inferior (margin 12%), and efficacy was statistically significant either for the overall intention-to treat (ITT) or the proximal-segment DCB groups lie, the proximal two-thirds of the below-knee arterial pathways). Results. Freedom from MALE-POD for the DCB group (99.3%) was non-inferior to PTA (99.4%; non-inferiority P<.001). Proportional analysis of the primary efficacy endpoint was statistically significant for the proximal-segment DCB group (76%) vs PTA (62.9%; one-sided P<.01; Bayesian P-value for success of 0085) while not statistically significant for the overall ITT group (74.5% for DCB vs 63.5% for PTA: one-sided P=.02). Kaplan-Meier analyses demonstrated superior efficacy for DCB in both the overall ITT and proximal-segment groups at 6 months. Primary patency and CD-TLR, hypothesis-tested secondary endpoints, were also statistically better for the DCB group compared with PTA at 6 months (one-sided P<.025). Conclusions. DCB treatment for symptomatic infrapopliteal arterial lesions produced non-inferior safety at 30 days and a statistically significant difference in the primary efficacy endpoint when compared with PTA at 6 months.Keywords
This publication has 22 references indexed in Scilit:
- Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stenting for the Treatment of Infrapopliteal Long-Segment Arterial Occlusive DiseaseJACC: Cardiovascular Interventions, 2014
- Calcium Burden Assessment and Impact on Drug-Eluting Balloons in Peripheral Arterial DiseaseCardioVascular and Interventional Radiology, 2014
- Drug-Eluting Balloon in Peripheral Intervention for Below the Knee Angioplasty Evaluation (DEBATE-BTK)Circulation, 2013
- Critical appraisal of surgical revascularization for critical limb ischemiaJournal of Vascular Surgery, 2013
- A Prospective Randomized Multicenter Comparison of Balloon Angioplasty and Infrapopliteal Stenting With the Sirolimus-Eluting Stent in Patients With Ischemic Peripheral Arterial DiseaseJournal of the American College of Cardiology, 2012
- Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive diseaseJournal of Vascular Surgery, 2011
- Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trialEuropean Heart Journal, 2011
- Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: An intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategyJournal of Vascular Surgery, 2010
- Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemiaJournal of Vascular Surgery, 2008
- Paclitaxel Balloon Coating, a Novel Method for Prevention and Therapy of RestenosisCirculation, 2004